Premium
Headache (45)
Author(s) -
Schulman Elliot A.,
Cady Roger K.,
Henry Dan
Publication year - 2001
Publication title -
pain practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 58
eISSN - 1533-2500
pISSN - 1530-7085
DOI - 10.1111/j.1533-2500.2001.1011-45.x
Subject(s) - sumatriptan , placebo , migraine , medicine , anesthesia , work productivity , clinical trial , randomized controlled trial , surgery , productivity , alternative medicine , receptor , macroeconomics , pathology , economics , agonist
Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double blind, placebo‐controlled clinical trial. (Center for Headache Management, Springfield, PA) Mayo Clin Proc 2000;75:782–789. This clinical trial determined the effect of sumatriptan on migraine‐related workplace productivity loss. Adult migraine sufferers self‐injected 6 mg of sumatriptan or matching placebo to treat a moderate or severe migraine within the first 4 h of a minimum of an 8‐h work shift. Outcome measures included productivity loss and number of patients returning to normal work performance 2 h after injection and across the work shift, time to return to normal work performance, and time to headache relief. A total of 206 patients underwent screening, 140 (safety population) of whom returned for clinic treatment. Of these 140 patients, 119 received migraine treatment in the workplace. Sumatriptan treatment tended to reduce median productivity loss 2 h after injection compared with placebo (25.2 versus 29.9 min, respectively) ( P = 0.14). Significant reductions in productivity loss were obtained across the work shift after sumatriptan treatment compared with placebo (36.8 versus 72.6, respectively) ( P = 0.001). Significantly more sumatriptan‐treated patients versus placebo‐treated patients experienced shorter return to normal work performance at 2 h and across the work shift. Significantly more sumatriptan‐treated patients experienced headache relief 1 h after injection compared with placebo‐treated patients. Conclude that across an 8‐h work shift, sumatriptan was superior to the placebo in reducing productivity loss due to migraine.